A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

NCT03661320 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

855

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder Neoplasms
Muscle-Invasive Bladder Cancer

Interventions

BIOLOGICAL: Nivolumab
DRUG: Gemcitabine
DRUG: Cisplatin

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]